Cited by

• IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells.

  Cui L, Deng Y, Rong Y, Lou W, Mao Z, Feng Y, Xie D, Jin D. Cui L, et al. Tumour Biol. 2012 Feb;33(1):247-55. doi: 10.1007/s13277-011-0273-3. Epub 2011 Nov 26. Tumour Biol. 2012. PMID: 22119988
• Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions.

  Amedei A, Niccolai E, Benagiano M, Della Bella C, Cianchi F, Bechi P, Taddei A, Bencini L, Farsi M, Cappello P, Prisco D, Novelli F, D'Elios MM. Amedei A, et al. Cancer Immunol Immunother. 2013 Jul;62(7):1249-60. doi: 10.1007/s00262-013-1429-3. Epub 2013 May 3. Cancer Immunol Immunother. 2013. PMID: 23640603 Free PMC article.
• Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.

  Karakhanova S, Link J, Heinrich M, Shevchenko I, Yang Y, Hassenpflug M, Bunge H, von Ahn K, Brecht R, Mathes A, Maier C, Umansky V, Werner J, Bazhin AV. Karakhanova S, et al. Oncoimmunology. 2015 Jan 22;4(4):e998519. doi: 10.1080/2162402X.2014.998519. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137414 Free PMC article.
• IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.

  Zhou H, Qian W, Uckun FM, Wang L, Wang YA, Chen H, Kooby D, Yu Q, Lipowska M, Staley CA, Mao H, Yang L. Zhou H, et al. ACS Nano. 2015 Aug 25;9(8):7976-91. doi: 10.1021/acsnano.5b01288. Epub 2015 Aug 10. ACS Nano. 2015. PMID: 26242412 Free PMC article.
• Potential of Carbohydrate Antigen 19-9 and Serum Apolipoprotein A2-Isoforms in the Diagnosis of Stage 0 and IA Pancreatic Cancer.

  Hanada K, Shimizu A, Tsushima K, Kobayashi M. Hanada K, et al. Diagnostics (Basel). 2024 Aug 30;14(17):1920. doi: 10.3390/diagnostics14171920. Diagnostics (Basel). 2024. PMID: 39272705 Free PMC article.